Logo

Prestige Biopharma Reports the CHMP’s Positive Opinion of Tuznue (Biosimilar, Herceptin)

Share this
Prestige Biopharma

Prestige Biopharma Reports the CHMP’s Positive Opinion of Tuznue (Biosimilar, Herceptin)

Shots:

  • The CHMP has granted positive opinion to Tuznue, a biosimilar version of Herceptin (trastuzumab) for the treatment of HER2+ve early & metastatic breast cancer as well as HER2+ve metastatic gastric cancer
  • The recommendation was supported by the data showing similarity b/w Tuznue vs Herceptin under P-I & P-III trials to evaluate the PK profile, safety & immunogenicity among healthy volunteers & HER2+ve early breast cancer patients, respectively
  • In addition, Prestige has already entered into licensing agreements with Dr. Reddy’s, Tabuk, Cipla & Pharmapark for its marketing & sales worldwide, triggering milestone payments; negotiations are ongoing for market entry across the EU

Ref: Prestige Biopharma | Image: Prestige Biopharma

Related News: The EMA Rejects Prestige BioPharma’s Tuznue and Hervelous, a proposed biosimilars of trastuzumab for HER2-Positive Breast and Gastric Cancers

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions